CN105213351A - For the pad pasting that hypertrophic cicatrix is repaired - Google Patents
For the pad pasting that hypertrophic cicatrix is repaired Download PDFInfo
- Publication number
- CN105213351A CN105213351A CN201510643629.2A CN201510643629A CN105213351A CN 105213351 A CN105213351 A CN 105213351A CN 201510643629 A CN201510643629 A CN 201510643629A CN 105213351 A CN105213351 A CN 105213351A
- Authority
- CN
- China
- Prior art keywords
- gamma interferon
- sticky polymer
- dispelling
- liposome
- pad pasting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of pad pasting repaired for hypertrophic cicatrix, pad pasting of the present invention comprises backing layer bonding successively, sticky polymer nitride layer and sealing coat, described sticky polymer nitride layer comprises sticky polymer thing, liposome permeation enhancers and scar active component of dispelling, good cohesive and caking property can be kept when dampness or perspiration, and there is good hydrophilic and lipotropy simultaneously, more be conducive to medicine transdermal, promote the absorption of medicine, higher drugs through skin rate can be obtained.Pad pasting instant effect for hypertrophic cicatrix reparation of the present invention, short treating period and not easily recurring.Its preparation method is simple, process costs is low.
Description
Technical field
The present invention relates to cicatrix recovery technique field, particularly relate to a kind of pad pasting repaired for hypertrophic cicatrix.
Background technology
Hypertrophic cicatrix, is mainly in lesion depths only and after the wound of corium and the wound healing of deep burn.The pathological tissue difference of hypertrophic cicatrix and abnormal scar is only thickening of cicatrix deep collagen fiber, shows as irregular arrangement, or in great waves shape, or be wound in cord-like.Hypertrophic cicatrix rises when generation, is just ceaselessly changing.From the beginning of when, the fibroplasia of cicatrix is very fast, a lot, and after fibroplasia too much, the normal blood vessel by cicatrix inside presses off, and makes its ischemia gradually, hypertrophic cicatrix shows as protuberate, and profile is irregular, is uneven, flushing is congested, and matter is real tough, has causalgia and scratchiness.Common are the scar of otch after sewing up and just belong to this one.
At present, the therapies such as the topical remedy of the many employings for the treatment of hypertrophic cicatrix both at home and abroad closes, skin transplantation, excision skin-grafting, pressure therapy, crystal mill scar art, be not very ripe clinically, curative effect has to be seen.And the required time had is long, painful large, easily repeatedly, there is adverse consequences etc., many all not fully up to expectations.
Summary of the invention
The object of this invention is to provide a kind of pad pasting repaired for hypertrophic cicatrix, good cohesive and caking property can be kept when dampness or perspiration, and there is good hydrophilic and lipotropy simultaneously, more be conducive to medicine transdermal, promote the absorption of medicine, higher drugs through skin rate can be obtained.
Another object of the present invention is to provide a kind of preparation method of described pad pasting.
The technical scheme adopted for realizing object of the present invention is: a kind of pad pasting repaired for hypertrophic cicatrix, comprise backing layer bonding successively, sticky polymer nitride layer and sealing coat, described sticky polymer nitride layer comprises sticky polymer thing, liposome permeation enhancers and scar active component of dispelling.
The weight of described sticky polymer thing, liposome permeation enhancers and scar active component of dispelling is: sticky polymer thing 550-950 part, liposome permeation enhancers 300-500 part, scar of dispelling active component 10-20 part, glycerol 850-1500 part.
Described sticky polymer thing adopts polyacrylate pressure-sensitive.
Described liposome permeation enhancers comprises lecithin, sodium cholate and stearmide, and the weight of described lecithin, sodium cholate and stearmide is: lecithin 80-90 part, sodium cholate 20-30 part, stearmide 7-10 part.
Described scar active component of dispelling comprises gamma interferon, Va acid and Ve, and the weight of described gamma interferon, Va acid and Ve is: gamma interferon 650-750 part, Va acid 12-20 part, Ve11-20 part.
Described gamma interferon adopts Monoclonal Antibodies Against Human Recombinant Interferon-gamma.
Described backing layer is polyurethanes film, and described sealing coat adopts release paper.
The present invention adopts the homogeneous mixture of sticky polymer thing, liposome permeation enhancers and scar active component of dispelling as sticky polymer nitride layer material, sticky polymer thing adopts polyacrylate pressure-sensitive, have low temperature resistant, high temperature resistant preferably, volatile matter can be coagulated and mass loss rate is low, and without the characteristic of harmful gas effusion, oil resistivity and solvent resistance excellent, adhesion and cohesiveness high, the transparency is good, under long-term stress effect, creep resistance is also excellent, as slow-released carrier, there is good slow release effect and autohension; Interferon is encapsulated in liposome by liposome permeation enhancers, interferon is played to the effect of slow release and controlled release, also improve the stability of interferon simultaneously, liposome bilayers and biomembrane have larger similarity, and there is good histocompatibility, be easy to tissue resorption, effectively promote the absorption of skin to interferon, also can protect good autohension and Penetration enhancing effect when dampness or perspiration; Therefore, have effectively achieved and keep good cohesive and caking property when dampness or perspiration, and there is good hydrophilic and lipotropy simultaneously, be more conducive to medicine transdermal, promote the effect of drug absorption.
Cover and have on good flexible backing layer; be attached to soft comfortable on skin, backing layer has the effect covering and protect drug depot, avoids the scar active component of dispelling of sticky polymer nitride layer to external diffusion; make ingredient more to the infiltration of skin direction, improve drug effect.Sealing coat has good protective effect to sticky polymer nitride layer, avoids contaminated, can cling sticky polymer nitride layer and be easy to again the two separately.
Gamma interferon, Va acid, Ve all have good inhibition to hypertrophic cicatrix.Gamma interferon belongs to II type interferon, produces primarily of activating T cell, NK cell, can antiviral, cell proliferation, and activating macrophage promotes that HLAI and II quasi-molecule is expressed, and promotes that Th0 cell differentiation is Th1 cell, suppresses Th2 cell proliferation; Promote cytotoxic T cell maturation and killing activity, promote B cell differentiation, produce antibody and immunoglobulin class conversion, activate neutrophilic granulocyte, promote NK cell killing activity, activate vascular endothelial cell etc., be a kind of antiviral bioactive substance efficiently, there is extensive immunoregulation effect.The Va acid nexine that penetrates to the skin can improve coarse skin quality, growth promoting effects, and can promote that epidermal area corneocyte divides normalization, makes epithelium keep normal.Va acid promotes skin metabolism, improves the coarse, dry of skin, makes gloomy skin seem to have gloss; Perfect skin keratin layer tissue, strengthen elasticity, the transparent feel of skin, make skin seem tender, pale, more healthy; Remove the foul be deposited in pore, pore refining, has antibacterial action.But have certain zest, notice that concentration can not be too high, excessive use can allow keratodermatitis too thin on the contrary and cause allergy.Ve has antioxidation, can prevent the oxidation of fatty compound, Va acid, improves the effect of Va acid; A kind of very important vasodilation and anticoagulant; Can scavenging free radicals, protection skin tissue, promote Dermal microvessel circulation, make the blood in skin forever bright clean, skin is naturally ruddy vigor.
The present invention is for repairing the scar gel film of dispelling of hypertrophic cicatrix, and backing layer has good pliability, is attached to soft comfortable on skin, has the effect covering and protect drug depot; Gummy polymer layers with organic pressure-sensitive gel class sticky polymers for controlled release matrix material, after the scar active component of dispelling of doses is contained in liposome permeation enhancers, be uniformly distributed in skeleton with the form of microcoulomb, by changing the content of sticky polymers Chinese medicine, the density of microcoulomb, the state of liposome regulates in scar gel film of dispelling the rate of release of scar active component of dispelling.Liposome permeation enhancers adopts lecithin and sodium cholate as liposome structure, for flexible lipidosome, one both sexes, have good hydrophilic and lipotropy, hydrophilic matrix transdermal drug delivery system has higher water content simultaneously, can be used for flexible lipidosome hydrated environment, more be conducive to medicine transdermal, lecithin itself, also as transdermal enhancer, promotes the absorption of medicine, therefore can obtain higher drugs through skin rate; Lipophilic system can effectively absorb affected part secretions, accelerates lump software implementation, repairs cicatrix.Pad pasting instant effect for hypertrophic cicatrix reparation of the present invention, short treating period and not easily recurring.
Detailed description of the invention
The present invention is used for the pad pasting that hypertrophic cicatrix is repaired, there is good autohension and slow release, controlled release, transdermal effect, good cohesive and caking property can be kept when dampness or perspiration, and there is good hydrophilic and lipotropy simultaneously, more be conducive to medicine transdermal, promote the absorption of medicine, higher drugs through skin rate can be obtained, it comprises backing layer bonding successively, sticky polymer nitride layer and sealing coat, and described sticky polymer nitride layer comprises sticky polymer thing, liposome permeation enhancers and scar active component of dispelling.Backing layer is pliable and tough, comfortable, covers and protection drug depot, makes to dispel scar active component to the infiltration of skin direction, improves drug effect; Sticky polymer nitride layer slow release, controlled release, keep good cohesive, caking property, hydrophilic and lipotropy, be beneficial to medicine transdermal when dampness or perspiration, promote the absorption of medicine;
As preferred version of the present invention: the weight of described sticky polymer thing, liposome permeation enhancers and scar active component of dispelling is: sticky polymer thing 200-950 part, liposome permeation enhancers 100-500 part, scar of dispelling active component 1-20 part, glycerol 500-1500 part; Described sticky polymer thing adopts polyacrylate pressure-sensitive.Through applicant's experimentation and clinical practice application for many years, adopt the sticky polymer nitride layer of described weight, good hydrophilic and lipotropy can be had concurrently simultaneously, good relatively better cohesive and caking property can be kept when dampness or perspiration.
As the further prioritization scheme of the present invention: described liposome permeation enhancers comprises lecithin, sodium cholate and stearmide, the weight of described lecithin, sodium cholate and stearmide is: lecithin 60-90 part, sodium cholate 10-30 part, stearmide 1-10 part.Adopt the liposome permeation enhancers of described heavy part proportioning, in scar of dispelling active component, the package rate of interferon reaches more than 84.6, and the rate of release of scar of dispelling active component and infiltration rate can reach best compatibility status, use pad pasting medicine instant effect and the drug effect phase long; Good hydrophilic and lipotropy can be kept simultaneously, subsidize each other, promote drug absorption, accelerating wound healing.
As the scheme of one-step optimization more of the present invention: described in scar active component of dispelling comprise gamma interferon, Va acid and Ve, described gamma interferon, Va acid and the weight of Ve are: gamma interferon 70-750 part, Va acid 1-20 part, Ve5-20 part.Adopt the scar active component of dispelling of described proportioning, use the drug effect of gamma interferon to obtain maximum performance, and the synergism of Va acid and Ve reaches most perfect condition, cicatrix remediation efficiency is better.
Further optimization technical scheme of the present invention: described gamma interferon adopts Monoclonal Antibodies Against Human Recombinant Interferon-gamma.Good effect, cost are low; Described backing layer is polyurethanes film, and pliability is better, it is better to be affixed on skin comfort; Described sealing coat adopts release paper; sticky polymer nitride layer can be clung; be easy to again make both be separated; not with resin system generation chemical reaction or pollute resin system; when ambient temperature and humidity changes; length, the width of release paper all should remain unchanged; efficiently avoid and to make sticky polymer nitride layer fold because release paper is wrinkling and in preparation process, cause the generation of distortion or distorting event because drawing-off is asynchronous; there is good compactness; prevent moisture etc. from passing through, protection sticky polymer nitride layer is not contaminated.
The preparation method of above-mentioned pad pasting, comprises the following steps:
1) gamma interferon solution is prepared:
A. get the gamma interferon of described weight portion, the activity being diluted to gamma interferon with the PBS containing human blood protein 0.5-1.0% is 0.3-0.6 × 10
8iU/ml, for subsequent use after aseptic filtration; PBS is phosphate buffer, and for molecular cloning and cell culture, pH=7.4, isotonic with blood of human body, main component is potassium dihydrogen phosphate, sodium hydrogen phosphate, sodium chloride and potassium chloride.
2) the liposome permeation enhancers of described weight portion is prepared:
B. getting the lecithin of described weight, sodium cholate and stearmide is dissolved in the ethanol of 80-400 part, at 28-33 DEG C, carry out decompression rotary evaporation, and rotating speed controls, at 90-110rpm, to evaporate completely to ethanol;
3) gamma interferon is encapsulated in liposome, obtained gamma interferon liposome liquid:
C. the gamma interferon diluent prepared by step a joins in the liposome permeation enhancers prepared by step b, and obtained Liposomal suspensions also carries out ultrasonic disperse; Adopt ultrasonic disperse technology, efficiency is high, and effective, drastically increases the envelop rate of gamma interferon;
D. adopt polydextran gel (sephadexG-50) to carry out column chromatography, collect first eluting peak liquid; Effectively liposome permeation enhancers and the gamma interferon be encapsulated in wherein can be separated by column chromatography.
E. adopt the microporous filter membrane of 0.20-0.24 μm to carry out aseptic filtration to collected eluting peak liquid, obtain gamma interferon liposome liquid, for subsequent use at being stored in 4 DEG C; In described gamma interferon liposome liquid, the content of gamma interferon (active unit) is 10
4-10
9iU/1m, envelop rate are more than 85%; Greatly ensured the drug effect of pad pasting, instant effect and the drug effect phase long.
4) gummy polymer layers mixed liquor is prepared:
F. the sticky polymers of obtained gamma interferon liposome liquid and described weight, glycerol, Va is sour and Ve is mixed homogeneously, and can obtain gummy polymer layers mixed liquor.
5) coated and molded, finished product of cutting into slices to obtain:
G. the gummy polymer layers mixed liquor of mix homogeneously is uniformly coated on backing layer, dried 1-3h at 38-40 DEG C, can gummy polymer layers be obtained, be cooled to room temperature, section, the pad pasting and the upper sealing coat of covering gets product.
Embodiment one
For the pad pasting that hypertrophic cicatrix is repaired, it comprises backing layer bonding successively, sticky polymer nitride layer and sealing coat, and described sticky polymer nitride layer comprises sticky polymer thing, liposome permeation enhancers and scar active component of dispelling.
The weight of described sticky polymer thing, liposome permeation enhancers and scar active component of dispelling is: sticky polymer thing 200 parts, liposome permeation enhancers 100 parts, scar of dispelling active component 1 part, glycerol 500 parts;
Described liposome permeation enhancers comprises lecithin, sodium cholate and stearmide, and the weight of described lecithin, sodium cholate and stearmide is: 60 parts, lecithin, sodium cholate 10 parts, stearmide 1 part.
Described scar active component of dispelling comprises gamma interferon, Va acid and Ve, and the weight of described gamma interferon, Va acid and Ve is: gamma interferon 70 parts, Va acid 1 part, Ve5 part.
Described gamma interferon adopts Monoclonal Antibodies Against Human Recombinant Interferon-gamma, and described backing layer is polyurethanes film, and described sealing coat adopts release paper.
Its preparation method, comprises the following steps:
1) gamma interferon solution is prepared:
A. get the gamma interferon of described weight portion, the activity being diluted to gamma interferon with the PBS containing human blood protein 0.5% is 0.3 × 10
8iU/ml, for subsequent use after aseptic filtration;
2) the liposome permeation enhancers of described weight portion is prepared:
B. getting the lecithin of described weight, sodium cholate and stearmide is dissolved in the ethanol of 80 parts, and at 28 DEG C, carry out decompression rotary evaporation, rotating speed is 90rpm, evaporates completely to ethanol;
3) gamma interferon is encapsulated in liposome, obtained gamma interferon liposome liquid:
C. the gamma interferon diluent prepared by step a joins in the liposome permeation enhancers prepared by step b, and obtained Liposomal suspensions also carries out ultrasonic disperse;
D. adopt polydextran gel (sephadexG-50) to carry out column chromatography, collect first eluting peak liquid;
E. adopt the microporous filter membrane of 0.20 μm to carry out aseptic filtration to collected eluting peak liquid, obtain gamma interferon liposome liquid, for subsequent use at being stored in 4 DEG C; In described gamma interferon liposome liquid, the content of gamma interferon (active unit) is 10
4-10
9iU/1m, envelop rate are more than 85%;
4) gummy polymer layers mixed liquor is prepared:
F. the sticky polymers of obtained gamma interferon liposome liquid and described weight, glycerol, Va is sour and Ve is mixed homogeneously, and can obtain gummy polymer layers mixed liquor.
5) coated and molded, finished product of cutting into slices to obtain:
G. be uniformly coated on backing layer by the gummy polymer layers mixed liquor of mix homogeneously, at 38 DEG C, dry 1h, is cooled to room temperature, section, the pad pasting and the upper sealing coat of covering gets product.
Embodiment two
For the pad pasting that hypertrophic cicatrix is repaired, it comprises backing layer bonding successively, sticky polymer nitride layer and sealing coat, and described sticky polymer nitride layer comprises sticky polymer thing, liposome permeation enhancers and scar active component of dispelling.
The weight of described sticky polymer thing, liposome permeation enhancers and scar active component of dispelling is: sticky polymer thing 550 parts, liposome permeation enhancers 300 parts, scar of dispelling active component 10 parts, glycerol 850 parts;
Described liposome permeation enhancers comprises lecithin, sodium cholate and stearmide, and the weight of described lecithin, sodium cholate and stearmide is: 80 parts, lecithin, sodium cholate 20 parts, stearmide 7 parts.
Described scar active component of dispelling comprises gamma interferon, Va acid and Ve, and the weight of described gamma interferon, Va acid and Ve is: gamma interferon 650 parts, Va acid 12 parts, Ve11 part.
Described gamma interferon adopts Monoclonal Antibodies Against Human Recombinant Interferon-gamma.
Described backing layer is polyurethanes film; Described sealing coat adopts release paper.
Its preparation method, comprises the following steps:
1) gamma interferon solution is prepared:
A. get the gamma interferon of described weight portion, the activity being diluted to gamma interferon with the PBS containing human blood protein 0.8% is 0.5 × 10
8iU/ml, for subsequent use after aseptic filtration;
2) the liposome permeation enhancers of described weight portion is prepared:
B. getting the lecithin of described weight, sodium cholate and stearmide is dissolved in the ethanol of 300 parts, and at 31 DEG C, carry out decompression rotary evaporation, rotating speed is 100rpm, evaporates completely to ethanol;
3) gamma interferon is encapsulated in liposome, obtained gamma interferon liposome liquid:
C. the gamma interferon diluent prepared by step a joins in the liposome permeation enhancers prepared by step b, and obtained Liposomal suspensions also carries out ultrasonic disperse;
D. adopt polydextran gel (sephadexG-50) to carry out column chromatography, collect first eluting peak liquid; Effectively liposome permeation enhancers and the gamma interferon be encapsulated in wherein can be separated by column chromatography.
E. adopt the microporous filter membrane of 0.22 μm to carry out aseptic filtration to collected eluting peak liquid, obtain gamma interferon liposome liquid, for subsequent use at being stored in 4 DEG C; In described gamma interferon liposome liquid, the content of gamma interferon (active unit) is 10
6iU/1m, envelop rate are more than 87%;
4) gummy polymer layers mixed liquor is prepared:
F. the sticky polymers of obtained gamma interferon liposome liquid and described weight, glycerol, Va is sour and Ve is mixed homogeneously, and can obtain gummy polymer layers mixed liquor.
5) coated and molded, finished product of cutting into slices to obtain:
G. the gummy polymer layers mixed liquor of mix homogeneously is uniformly coated on backing layer, dried 2h at 39 DEG C, can gummy polymer layers be obtained, be cooled to room temperature, section, the pad pasting and the upper sealing coat of covering gets product.
Embodiment three
For the pad pasting that hypertrophic cicatrix is repaired, it comprises backing layer bonding successively, sticky polymer nitride layer and sealing coat, and described sticky polymer nitride layer comprises sticky polymer thing, liposome permeation enhancers and scar active component of dispelling.
The weight of described sticky polymer thing, liposome permeation enhancers and scar active component of dispelling is: sticky polymer thing 950 parts, liposome permeation enhancers 500 parts, scar of dispelling active component 20 parts, glycerol 1500 parts;
Described liposome permeation enhancers comprises lecithin, sodium cholate and stearmide, and the weight of described lecithin, sodium cholate and stearmide is: 90 parts, lecithin, sodium cholate 30 parts, stearmide 10 parts.
Described scar active component of dispelling comprises gamma interferon, Va acid and Ve, and the weight of described gamma interferon, Va acid and Ve is: gamma interferon 750 parts, Va acid 20 parts, Ve20 part.
Described gamma interferon adopts Monoclonal Antibodies Against Human Recombinant Interferon-gamma.
Described backing layer is polyurethanes film; Described sealing coat adopts release paper.
Its preparation method, comprises the following steps:
1) gamma interferon solution is prepared:
A. get the gamma interferon of described weight portion, the activity being diluted to gamma interferon with the PBS containing human blood protein 1.0% is 0.6 × 10
8iU/ml, for subsequent use after aseptic filtration;
2) the liposome permeation enhancers of described weight portion is prepared:
B. getting the lecithin of described weight, sodium cholate and stearmide is dissolved in the ethanol of 400 parts, and at 33 DEG C, carry out decompression rotary evaporation, rotating speed is 110rpm, evaporates completely to ethanol;
3) gamma interferon is encapsulated in liposome, obtained gamma interferon liposome liquid:
C. the gamma interferon diluent prepared by step a joins in the liposome permeation enhancers prepared by step b, and obtained Liposomal suspensions also carries out ultrasonic disperse;
D. adopt polydextran gel (sephadexG-50) to carry out column chromatography, collect first eluting peak liquid; Effectively liposome permeation enhancers and the gamma interferon be encapsulated in wherein can be separated by column chromatography.
E. adopt the microporous filter membrane of 0.24 μm to carry out aseptic filtration to collected eluting peak liquid, obtain gamma interferon liposome liquid, for subsequent use at being stored in 4 DEG C; In described gamma interferon liposome liquid, the content of gamma interferon (active unit) is 10
9iU/1m, envelop rate are more than 88%;
4) gummy polymer layers mixed liquor is prepared:
F. the sticky polymers of obtained gamma interferon liposome liquid and described weight, glycerol, Va is sour and Ve is mixed homogeneously, and can obtain gummy polymer layers mixed liquor.
5) coated and molded, finished product of cutting into slices to obtain:
G. the gummy polymer layers mixed liquor of mix homogeneously is uniformly coated on backing layer, dried 3h at 40 DEG C, can gummy polymer layers be obtained, be cooled to room temperature, section, the pad pasting and the upper sealing coat of covering gets product.
Embodiment four
In March, 2011-July, select Zhengzhou patient in hospital, person 60 experimenters that include hypertrophic cicatrix in, test adopts the clinical verification method of random packet, standard control, test group 30 example and matched group 30 routine.All cases completed according to the observation cycle, and without rejecting, come off case.All participation clinical verifications tested all in line with the principle of voluntary participation clinical trial, understanding the object of clinical verification, process and time limit, and use checking apparatus to the effect in clinical be benefited and risk that instrumentation may run into and should take measure when, obtain experimenter completely to agree to, signature Informed Consent Form.Actual MethodsThe cases enrolled 60 example, without dropping by the wayside or dropping situations.
Test group and matched group experimenter sex, age, height, the more equal not statistically significant of body weights; To the course of disease, hypertrophic cicatrix Crack cause, the more equal not statistically significant of skin area situation.The thickness of skin scar, hardness, sensation, color and area according to index weights score value contrast test group not statistically significant more equal to matched group, point reasonable set.Test group and matched group comparitive study not statistically significant, illustrate that test products and reference product have equivalence.Person 30 example that test products is used for the treatment of hypertrophic cicatrix, occurs without adverse events, illustrates that the safety of product is higher.
Model case 1
Zhang, female, 24 years old, scar hyperplasia after finishing caesarean operation, often produced pruritus and with burning sensation, softens cicatrix, do not have effect with other ointment.Treat cicatrix place through scar gel film of dispelling with the present invention, do not cause ill symptoms, after two weeks, cicatrix obviously improves, after two wheat harvesting periods, and the smooth nature of exquisiteness that skin becomes, and without recurrence.
Model case 2
Shut out certain, man, 30 years old, causes little leg outer side to scratch in traffic accident, and after simple therapy, formation 10 centimeters of hypertrophic cicatriies, limitation of activity, handicapped, seeks medical advice everywhere, have no resolution; After in clinical trial, use the present invention to be used for repairing hypertrophic cicatrix scar gel film of dispelling carry out clinical trial, after continuously using 30 days, cicatrix obviously reduces, after 70 days, cicatrix disappears, without sharp trace, and rear continuous use 15 days, return to one's perfect health, skin recovers normal, and the later stage pays a return visit without recurrence.
Model case 3
Zhu, man, 41 years old, right arm III degree scald, because of malpractice, forms hypertrophic cicatrix, there is lump local, having pain, using the scar gel film of dispelling for repairing hypertrophic cicatrix of the present invention to treat upon somebody's introduction time firmly, continuous use is after 20 days, and lump starts to soften, and after 40 days, lump disappears, cicatrix reduces, cicatrix after 70 days, and skin is smooth, the colour of skin is thin out, return to one's perfect health after 90 days, skin recovers normal, and the later stage pays a return visit without recurrence.
Claims (3)
1., for the pad pasting that hypertrophic cicatrix is repaired, comprise backing layer bonding successively, sticky polymer nitride layer and sealing coat, it is characterized in that: described sticky polymer nitride layer comprises sticky polymer thing, liposome permeation enhancers and scar active component of dispelling; The weight of described sticky polymer thing, liposome permeation enhancers and scar active component of dispelling is: sticky polymer thing 550-950 part, liposome permeation enhancers 300-500 part, scar of dispelling active component 10-20 part, glycerol 850-1500 part; Described sticky polymer thing adopts polyacrylate pressure-sensitive; Described liposome permeation enhancers comprises lecithin, sodium cholate and stearmide, and the weight of described lecithin, sodium cholate and stearmide is: lecithin 80-90 part, sodium cholate 20-30 part, stearmide 7-10 part; Described scar active component of dispelling comprises gamma interferon, Va acid and Ve, and the weight of described gamma interferon, Va acid and Ve is: gamma interferon 650-750 part, Va acid 12-20 part, Ve11-20 part.
2. as claimed in claim 1 for the pad pasting that hypertrophic cicatrix is repaired, it is characterized in that: described gamma interferon adopts Monoclonal Antibodies Against Human Recombinant Interferon-gamma.
3. as claimed in claim 1 for the pad pasting that hypertrophic cicatrix is repaired, it is characterized in that: described backing layer is polyurethanes film, described sealing coat adopts release paper.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510643629.2A CN105213351B (en) | 2013-09-25 | 2013-09-25 | Pad pasting for hyperplastic scar reparation |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310439270.8A CN103495155B (en) | 2013-09-25 | 2013-09-25 | For pad pasting that hypertrophic cicatrix is repaired and preparation method thereof |
| CN201510643629.2A CN105213351B (en) | 2013-09-25 | 2013-09-25 | Pad pasting for hyperplastic scar reparation |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310439270.8A Division CN103495155B (en) | 2013-09-25 | 2013-09-25 | For pad pasting that hypertrophic cicatrix is repaired and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105213351A true CN105213351A (en) | 2016-01-06 |
| CN105213351B CN105213351B (en) | 2018-03-13 |
Family
ID=49860474
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510643630.5A Active CN105250995B (en) | 2013-09-25 | 2013-09-25 | Hyperplastic scar repairs pad pasting and preparation method thereof |
| CN201310439270.8A Active CN103495155B (en) | 2013-09-25 | 2013-09-25 | For pad pasting that hypertrophic cicatrix is repaired and preparation method thereof |
| CN201510643629.2A Active CN105213351B (en) | 2013-09-25 | 2013-09-25 | Pad pasting for hyperplastic scar reparation |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510643630.5A Active CN105250995B (en) | 2013-09-25 | 2013-09-25 | Hyperplastic scar repairs pad pasting and preparation method thereof |
| CN201310439270.8A Active CN103495155B (en) | 2013-09-25 | 2013-09-25 | For pad pasting that hypertrophic cicatrix is repaired and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN105250995B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021022033A1 (en) | 2019-07-30 | 2021-02-04 | Leung Kai P | Layered composite for scar treatment and prevention |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104983721A (en) * | 2015-06-25 | 2015-10-21 | 河南行知专利服务有限公司 | Scar repairing paste |
| CN106727115B (en) * | 2016-12-13 | 2019-08-13 | 广东科玮生物技术股份有限公司 | A kind of face cream and preparation method thereof for hyperplastic scar reparation |
| CN107510884A (en) * | 2017-09-30 | 2017-12-26 | 河南汇博医疗股份有限公司 | A kind of Silica hydrogel elasticity scar plaster and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5958443A (en) * | 1991-10-30 | 1999-09-28 | Mdv Technologies, Inc. | Medical uses of in situ formed gels |
| CN1520792A (en) * | 2003-02-13 | 2004-08-18 | 上海东月医疗保健用品有限公司 | Filling type fortified scar plaster and method for making same |
| EP1847264A1 (en) * | 2005-01-31 | 2007-10-24 | Hisamitsu Pharmaceutical Co. Inc. | Patch |
| CN101754757A (en) * | 2007-05-25 | 2010-06-23 | 立德化学株式会社 | Medicated patch comprising 5-methyl-1-phenyl-2-(1h)-pyridone |
| CN202724121U (en) * | 2012-03-14 | 2013-02-13 | 南阳市汇博生物技术有限公司 | Cesarean scar removal restoration patch |
| CN103083282A (en) * | 2011-11-03 | 2013-05-08 | 杭州炬九生物科技有限公司 | Novel hydrogel scar patch and its preparation process |
| CN103127213A (en) * | 2011-12-02 | 2013-06-05 | 贵州金玖生物技术有限公司 | Dressing for removing scars |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN2320230Y (en) * | 1998-01-14 | 1999-05-26 | 上海东月医疗保健用品有限公司 | Scar-eliminating silica-gel film |
| CN1218693C (en) * | 2002-10-21 | 2005-09-14 | 马德林 | Adhesive film agent and its preparing method |
| CN202105203U (en) * | 2011-04-28 | 2012-01-11 | 上海市中医医院 | Sticking membrane for dermatosis and ulcer wound surface |
| CN103191460B (en) * | 2013-04-15 | 2014-10-29 | 潘银根 | Chitosan-silicone dressing as well as preparation method and application thereof |
-
2013
- 2013-09-25 CN CN201510643630.5A patent/CN105250995B/en active Active
- 2013-09-25 CN CN201310439270.8A patent/CN103495155B/en active Active
- 2013-09-25 CN CN201510643629.2A patent/CN105213351B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5958443A (en) * | 1991-10-30 | 1999-09-28 | Mdv Technologies, Inc. | Medical uses of in situ formed gels |
| CN1520792A (en) * | 2003-02-13 | 2004-08-18 | 上海东月医疗保健用品有限公司 | Filling type fortified scar plaster and method for making same |
| EP1847264A1 (en) * | 2005-01-31 | 2007-10-24 | Hisamitsu Pharmaceutical Co. Inc. | Patch |
| CN101754757A (en) * | 2007-05-25 | 2010-06-23 | 立德化学株式会社 | Medicated patch comprising 5-methyl-1-phenyl-2-(1h)-pyridone |
| CN103083282A (en) * | 2011-11-03 | 2013-05-08 | 杭州炬九生物科技有限公司 | Novel hydrogel scar patch and its preparation process |
| CN103127213A (en) * | 2011-12-02 | 2013-06-05 | 贵州金玖生物技术有限公司 | Dressing for removing scars |
| CN202724121U (en) * | 2012-03-14 | 2013-02-13 | 南阳市汇博生物技术有限公司 | Cesarean scar removal restoration patch |
Non-Patent Citations (2)
| Title |
|---|
| RUI ZHAO EET AL: "Transdermal siRNA-TGFβ1-337 patch for hypertrophic scar treatment", 《MATRIX BIOLOGY》 * |
| 杨勇等: "局部注射r-干扰素防治疤痕增生", 《中华医学会第六届全国烧伤外科学术会议论文汇编》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021022033A1 (en) | 2019-07-30 | 2021-02-04 | Leung Kai P | Layered composite for scar treatment and prevention |
| EP4003256A4 (en) * | 2019-07-30 | 2023-05-24 | Kai P. Leung | Layered composite for scar treatment and prevention |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103495155B (en) | 2015-10-14 |
| CN105250995A (en) | 2016-01-20 |
| CN105250995B (en) | 2018-06-22 |
| CN105213351B (en) | 2018-03-13 |
| CN103495155A (en) | 2014-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bing et al. | Randomized, multicenter, double‐blind, and placebo‐controlled trial using topical recombinant human acidic fibroblast growth factor for deep partial‐thickness burns and skin graft donor site | |
| Lima Júnior et al. | Pediatric burn treatment using tilapia skin as a xenograft for superficial partial-thickness wounds: a pilot study | |
| Freedman et al. | Breakthrough treatments for accelerated wound healing | |
| Singla et al. | Efficacy of topical application of beta urogastrone (recombinant human epidermal growth factor) in Wagner's Grade 1 and 2 diabetic foot ulcers: Comparative analysis of 50 patients | |
| Kelechi et al. | A randomized, investigator-blinded, controlled pilot study to evaluate the safety and efficacy of a poly-N-acetyl glucosamine–derived membrane material in patients with venous leg ulcers | |
| CN103495155B (en) | For pad pasting that hypertrophic cicatrix is repaired and preparation method thereof | |
| EP3484457B1 (en) | Topical formulation for promoting wound healing | |
| Schulz et al. | Our initial experience in the customized treatment of donor site and burn wounds with a new nanofibrous temporary epidermal layer | |
| US20200023044A1 (en) | Botulinum neurotoxins for treating traumatic injuries | |
| Kellar et al. | Improved wound closure rates and mechanical properties resembling native skin in murine diabetic wounds treated with a tropoelastin and collagen wound healing device | |
| Hao et al. | Dermlin and silver nanoparticles combined antibacterial dressing for skin wound repair | |
| Hasegawa et al. | Wound, pressure ulcer and burn guidelines–1: Guidelines for wounds in general | |
| WO2016090892A1 (en) | Water-soluble gel for treating diabetic foot | |
| Sabetkam et al. | Impact of mummy substance on proliferation and migration of human Wharton's jelly-derived stem cells and fibroblasts in an in vitro culture system. | |
| Farzamfar et al. | Diabetic foot ulcer | |
| US20220096709A1 (en) | Wound healing therapeutic hydrogels | |
| Bryan | Evaluation of Magnesium and Elastin Incorporation into Electrospun Chitosan Membranes for Skin Wounds | |
| WOUND | E-POSTER SESSION: ANTIMICROBIALS | |
| Rosselle | Development of biological models to test new treatments for chronic and infected wounds | |
| JP2023552515A (en) | Compositions and methods for treating wounds | |
| RANA | DEVELOPMENT OF CERAMIDE AND HONEY BASED BIODEGRADABLE DRESSING MATERIALS FOR THE APPLICATION TO BURN SKIN | |
| Punjataewakupt | Clinical efficacy of silk sericin dressing with collagen for split-thickness skin graft donor site treatment | |
| Dinesh | A Comparative study of Topical Platelet Derived Growth Factor (RH-PDGF) Versus Hydrogel Versus Normal Saline Dressing for Treating Diabetic Foot Ulcers | |
| CN116898954A (en) | Skin cell dispersion and its use in treating autologous burn | |
| CN112957519A (en) | Composition for preparing hydrogel for promoting wound healing, hydrogel and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 473300 West Section of Industrial Avenue, Industrial Agglomeration Area, Sheqi County, Nanyang City, Henan Province Patentee after: Henan Huibo Medical Co., Ltd. Address before: 473000 Wei three road, Lihe eco industrial park, Nanyang, Henan Patentee before: Nanyang Hui Bo Bioisystech Co., Ltd |